Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.